

Adverse periocular reactions to five types of prostaglan

Eye

26, 1465-1472

DOI: [10.1038/eye.2012.195](https://doi.org/10.1038/eye.2012.195)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Eyelash Growth Induced by Topical Prostaglandin Analogues, Bimatoprost, Tafluprost, Travoprost, and Latanoprost in Rabbits. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2013, 29, 817-820.	1.4	10
2	Therapeutic uses of prostaglandin F ₂ ± analogues in ocular disease and novel synthetic strategies. <i>Prostaglandins and Other Lipid Mediators</i> , 2013, 104-105, 109-121.	1.9	27
3	Managing adverse effects of glaucoma medications. <i>Clinical Ophthalmology</i> , 2014, 8, 903.	1.8	103
4	Travoprost with sofZia® preservative system lowered intraocular pressure of Japanese normal tension glaucoma with minimal side effects. <i>Clinical Ophthalmology</i> , 2014, 8, 347.	1.8	14
5	An evidence-based review of unoprostone isopropyl ophthalmic solution 0.15% for glaucoma: place in therapy. <i>Clinical Ophthalmology</i> , 2014, 8, 543.	1.8	10
6	Late-day intraocular pressureâ€“lowering efficacy and tolerability of travoprost 0.004% versus bimatoprost 0.01% in patients with open-angle glaucoma or ocular hypertension: a randomized trial. <i>BMC Ophthalmology</i> , 2014, 14, 151.	1.4	8
7	Bimatoprost: a unique compound that in its nonhydrolyzed form is a prostamide and hydrolyzed form has prostaglandin receptor activity, for glaucoma and cosmetic indications. <i>Expert Review of Ophthalmology</i> , 2014, 9, 159-173.	0.6	1
8	Determination of prostaglandin analogs in cosmetic products by high performance liquid chromatography with tandem mass spectrometry. <i>Journal of Chromatography A</i> , 2014, 1359, 140-146.	3.7	12
9	Fixed-combination treatments for intraocular hypertension in Chinese patients – focus on bimatoprost-timolol. <i>Drug Design, Development and Therapy</i> , 2015, 9, 2617.	4.3	4
10	Prostaglandin Analogueâ€“Induced Pigmentation of the Skin of the Nasal Septum and Nasal Alae in a Glaucoma Patient. <i>European Journal of Ophthalmology</i> , 2015, 25, e38-e39.	1.3	4
11	Hypertension secondary to treatment with latanoprost. <i>Archivos De La Sociedad Espanola De Oftalmologia</i> , 2015, 90, 37-39.	0.2	0
12	Safety and tolerability of the tafluprost/timolol fixed combination for the treatment of glaucoma. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 609-617.	2.4	18
14	Comparison study of intraocular pressure reduction efficacy and safety between latanoprost and tafluprost in Japanese with normal-tension glaucoma. <i>Clinical Ophthalmology</i> , 2016, Volume 10, 1633-1637.	1.8	13
15	The Association of Chronic Topical Prostaglandin Analog Use With Meibomian Gland Dysfunction. <i>Journal of Glaucoma</i> , 2016, 25, 770-774.	1.6	50
16	Oculoplastic considerations in patients withÂglaucoma. <i>Survey of Ophthalmology</i> , 2016, 61, 718-725.	4.0	18
17	Tafluprost Ophthalmic Solution 0.0015Â%: A Review in Glaucoma and Ocular Hypertension. <i>Clinical Drug Investigation</i> , 2016, 36, 499-508.	2.2	8
18	Periocular mexametric melanin and erythema indexes in adult glaucoma patients treated with topical prostaglandin analogs. <i>Cutaneous and Ocular Toxicology</i> , 2017, 36, 9-11.	1.3	0
19	Periorbital changes associated with prostaglandin analogs in Korean patients. <i>BMC Ophthalmology</i> , 2017, 17, 126.	1.4	16

#	ARTICLE	IF	CITATIONS
20	Tear biomarkers in latanoprost and bimatoprost treated eyes. PLoS ONE, 2018, 13, e0201740.	2.5	12
21	In Vivo Analysis of Prostaglandins-induced Ocular Surface and Periocular Adnexa Modifications in Patients with Glaucoma. In Vivo, 2018, 32, 211-220.	1.3	23
22	Phase 2, Randomized, Dose-finding Studies of Omidenepag Isopropyl, a Selective EP2 Agonist, in Patients With Primary Open-angle Glaucoma or Ocular Hypertension. Journal of Glaucoma, 2019, 28, 375-385.	1.6	43
24	Current Medical Therapy and Future Trends in the Management of Glaucoma Treatment. Journal of Ophthalmology, 2020, 2020, 1-14.	1.3	54
25	Omidenepag Isopropyl Versus Latanoprost in Primary Open-Angle Glaucoma and Ocular Hypertension. American Journal of Ophthalmology, 2020, 220, 53-63.	3.3	67
26	Comparison between Latanoprost, Travoprost, and Tafluprost in reducing intraocular pressure fluctuations in patients with glaucoma. European Journal of Ophthalmology, 2021, 31, 3018-3026.	1.3	3
27	Effects of topical prostaglandin drops on angiogenesis in an in ovo chick chorioallantoic membrane model. Cutaneous and Ocular Toxicology, 2021, 40, 54-60.	1.3	5
28	A Randomized Phase 2 Trial Comparing Omidenepag Isopropyl 0.002% Once and Twice Daily in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (SPECTRUM-6). Journal of Glaucoma, 2021, 30, 473-480.	1.6	11
29	Periocular invasive melanoma manifestation in a patient using bimatoprost: case report and literature review. Orbit, 2023, 42, 73-80.	0.8	2
30	Effects of selective EP2 receptor agonist, omidenepag, on trabecular meshwork cells, Schlemm's canal endothelial cells and ciliary muscle contraction. Scientific Reports, 2021, 11, 16257.	3.3	19
31	Twelve-month efficacy and safety of omidenepag isopropyl, a selective EP2 agonist, in open-angle glaucoma and ocular hypertension: the RENGE study. Japanese Journal of Ophthalmology, 2021, 65, 810-819.	1.9	24
32	Efficacy and safety of 0.0015% tafluprost versus 0.005% latanoprost in primary open angle glaucoma, ocular hypertension: a Meta-analysis. International Journal of Ophthalmology, 2020, 13, 474-480.	1.1	10
33	Short-Term Efficacy and Safety of Omidenepag Isopropyl in Patients with Normal-Tension Glaucoma. Clinical Ophthalmology, 2020, Volume 14, 2943-2949.	1.8	15
34	Present and New Treatment Strategies in the Management of Glaucoma. Open Ophthalmology Journal, 2015, 9, 89-100.	0.2	37
35	A new look at the safety and tolerability of prostaglandin analogue eyedrops in glaucoma and ocular hypertension. Expert Opinion on Drug Safety, 2022, 21, 525-539.	2.4	7
36	Eye Medications and Its Effect on Orbital Fat and Cosmesis. , 2020, , 51-63.		0
37	Periocular Adverse Reactions to Omidenepag Isopropyl. American Journal of Ophthalmology, 2022, 237, 114-121.	3.3	11
38	Efficacy of local prostaglandin analogues for vitiligo treatment: a systematic review and meta-analysis. Expert Review of Clinical Pharmacology, 2022, , 1-9.	3.1	0

#	ARTICLE	IF	CITATIONS
39	One-Year Efficacy and Safety of Omidenepag Isopropyl in Patients with Normal-Tension Glaucoma. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2022, 38, 354-358.	1.4	4
40	Association between personality traits and experience of adverse periocular reactions to topical prostaglandin analogues. <i>BMJ Open Ophthalmology</i> , 2022, 7, e000946.	1.6	0
41	Screening and quantification of undeclared PGF ₂ analogs in eyelash-enhancing cosmetic serums using LC-MS/MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2022, 219, 114940.	2.8	2
42	Glaucoma: pharmacological management and iatrogenic causes. <i>Journal of Prescribing Practice</i> , 2022, 4, 388-394.	0.1	0
43	Clinical Efficacy of Topical Tacrolimus on Conjunctival Hyperemia Caused by Prostaglandin Analogues. <i>Evidence-based Complementary and Alternative Medicine</i> , 2022, 2022, 1-6.	1.2	1
44	Impact of glaucoma medications on the ocular surface and how ocular surface disease can influence glaucoma treatment. <i>Ocular Surface</i> , 2023, 29, 456-468.	4.4	6
45	How latanoprost changed glaucoma management. <i>Acta Ophthalmologica</i> , 2024, 102, .	1.1	1
46	The budget impact of introducing the OMNIÂ® surgical system to a United States health plan for managing mild-to-moderate primary open-angle glaucoma. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 0, , 1-8.	1.4	1
47	Effects of Brimonidine, Omidenepag Isopropyl, and Ripasudil Ophthalmic Solutions to Protect against H ₂ O ₂ -Induced Oxidative Stress in Human Trabecular Meshwork Cells. <i>Current Eye Research</i> , 0, , 1-12.	1.5	0
48	Ocular surface disease: a known yet overlooked side effect of topical glaucoma therapy. <i>Frontiers in Toxicology</i> , 0, 5, .	3.1	3
49	Short-term Efficacy and Safety of Omidenepag Isopropyl 0.002% w/v Therapy for Patients with Primary Open-angle Glaucoma and Ocular Hypertension. <i>Journal of Korean Ophthalmological Society</i> , 2023, 64, 819-824.	0.2	0
50	Latanoprostene Bunod 0.024% w/v Treatment of Open-angle Glaucoma: Short-term Effects, Safety, and Changes in Ocular Blood. <i>Journal of Korean Ophthalmological Society</i> , 2023, 64, 930-938.	0.2	0
51	Prostaglandin FP receptor agonists in the treatment of glaucoma and ocular hypertension: a literature review. <i>Expert Opinion on Investigational Drugs</i> , 2023, 32, 1017-1023.	4.1	0
52	Myopic Shift After the Administration of Omidenepag Isopropyl in Patients with Normal-Tension Glaucoma. <i>Re:GEN Open</i> , 2023, 3, 52-56.	0.2	0
53	Effects of Topical Anti-Glaucoma Medications on Outcomes of Endoscopic Dacryocystorhinostomy: Comparison with Age- and Sex-Matched Controls. <i>Journal of Clinical Medicine</i> , 2024, 13, 634.	2.4	0
54	Preparation and characterization of vinyl silica-supported surface molecularly imprinted polymers coupled with liquid chromatography-mass spectrometry for extraction of prostaglandin analogs from cosmetic products. <i>Separation Science Plus</i> , 0, , .	0.6	0
55	Eyelash serums: A comprehensive review. <i>Journal of Cosmetic Dermatology</i> , 0, , .	1.6	0